心脏特异性LIM蛋白FHL2修改了对β-上腺刺激的高性反应
Y Kong1, J M Shelton, B Rothermel
1Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390-8573, USA.
Circulation
|June 8, 2001
概括
四半LIM域蛋白2 (FHL2) 不是正常心脏发育必不可少的,但在对β-上腺刺激的反应中加剧心脏缩.
科学领域:
- 心血管生物学 心血管生物学
- 分子心脏病学分子心脏病学
- 发展生物学 发展生物学
背景情况:
- 肌肉LIM蛋白质缺乏导致扩大心肌病.
- 其他LIM域蛋白在心脏功能中的作用仍然在很大程度上未被描述.
- 专注于FHL2,一种特定于心脏的LIM域蛋白.
研究的目的:
- 描述FHL2在心脏发育过程中的表达模式.
- 为了研究FHL2在成人心脏中的功能.
- 确定FHL2在心脏缩中的作用.
主要方法:
- 使用北方斑点,现场杂交和西部斑点检查了FHL2mRNA和蛋白质表达.
- 通过同源重组生成FHL2淘汰赛小鼠.
- 在对异二醇输液的反应中评估心脏缩.
主要成果:
- FHL2表达在心脏发生的早期被检测出来,并在成年人的心脏中局部化到心肌.
- FHL2淘汰赛小鼠表现出正常的心血管发育.
- 缺少FHL2显著夸大了在异二醇挑战后的心脏缩.
结论:
- FHL2 作为心脏细胞的早期标记物,是心脏特异性的 LIM 蛋白.
- 对于正常的心脏发育,FHL2是不可或缺的.
- FHL2调节了对β-上腺体刺激的过度缩性心脏反应.
更多相关视频
相关概念视频
Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cellular Adaptation II: Hypertrophy
Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...


